Amedisys Inc (AMED): Price and Financial Metrics


Amedisys Inc (AMED): $260.62

5.16 (+2.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AMED POWR Grades


  • AMED scores best on the Quality dimension, with a Quality rank ahead of 99.37% of US stocks.
  • AMED's strongest trending metric is Value; it's been moving up over the last 31 weeks.
  • AMED's current lowest rank is in the Value metric (where it is better than 37.02% of US stocks).

AMED Stock Summary

  • Amedisys Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 82.27% of US listed stocks.
  • With a year-over-year growth in debt of -29.22%, Amedisys Inc's debt growth rate surpasses merely 16.98% of about US stocks.
  • The volatility of Amedisys Inc's share price is greater than that of merely 12.13% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Amedisys Inc are PNR, MORN, HELE, SAM, and RBA.
  • Visit AMED's SEC page to see the company's official filings. To visit the company's web site, go to www.amedisys.com.

AMED Valuation Summary

  • AMED's EV/EBIT ratio is 36; this is 34.83% higher than that of the median Healthcare stock.
  • Over the past 243 months, AMED's EV/EBIT ratio has gone up 32.6.
  • AMED's price/earnings ratio has moved up 39.6 over the prior 243 months.

Below are key valuation metrics over time for AMED.

Stock Date P/S P/B P/E EV/EBIT
AMED 2020-07-14 3.3 9.8 52.0 37.9
AMED 2016-01-11 1.1 3.4 -193.9 422.2
AMED 2008-09-25 1.5 2.7 18.4 13.8
AMED 2007-12-24 2.0 3.0 21.3 12.7
AMED 2004-06-30 2.6 7.1 35.4 19.8
AMED 2002-10-17 0.5 3.0 6.0 5.4

AMED Growth Metrics

  • Its 5 year cash and equivalents growth rate is now at 211.67%.
  • The 4 year revenue growth rate now stands at 49.12%.
  • The 5 year net cashflow from operations growth rate now stands at 103.58%.
AMED's revenue has moved up $484,540,000 over the prior 30 months.

The table below shows AMED's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 2,116.978 336.919 201.676
2020-12-31 2,071.519 288.952 183.608
2020-09-30 2,021.492 298.26 166.112
2020-06-30 1,972.053 262.632 128.263
2020-03-31 1,979.978 187.976 127.331
2019-12-31 1,955.633 202 126.833

AMED Price Target

For more insight on analysts targets of AMED, see our AMED price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $330.25 Average Broker Recommendation 1.42 (Moderate Buy)

AMED Stock Price Chart Interactive Chart >

Price chart for AMED

AMED Price/Volume Stats

Current price $260.62 52-week high $325.12
Prev. close $255.46 52-week low $216.20
Day low $254.30 Volume 193,458
Day high $260.95 Avg. volume 204,268
50-day MA $256.16 Dividend yield N/A
200-day MA $267.19 Market Cap 8.49B

Amedisys Inc (AMED) Company Bio


Amedisys provides home health and hospice care services. It operates through two segments, Home Health and Hospice. The company was founded in 1982 and is based in Baton Rouge, Louisiana.

AMED Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$260.62$255.4 -1%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Amedisys Inc. To summarize, we found that Amedisys Inc ranked in the 54th percentile in terms of potential gain offered. In terms of the factors that were most noteworthy in this DCF analysis for AMED, they are:

  • Interest coverage, a measure of earnings relative to interest payments, is 24.88; that's higher than 81.25% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than just 15.29% of the free cash flow producing stocks we're observing.
  • AMED's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 49.6% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-3%
1%-2%
2%-1%
3%0%
4%1%
5%2%

LMAT, LCI, PCRX, TMO, and UNH can be thought of as valuation peers to AMED, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


AMED Latest News Stream


Event/Time News Detail
Loading, please wait...

AMED Latest Social Stream


Loading social stream, please wait...

View Full AMED Social Stream

Latest AMED News From Around the Web

Below are the latest news stories about Amedisys Inc that investors may wish to consider to help them evaluate AMED as an investment opportunity.

Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 28, 2021

EHC or AMED: Which Is the Better Value Stock Right Now?

EHC vs. AMED: Which Stock Is the Better Value Option?

Yahoo | July 26, 2021

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Pekic/E+ via Getty Images In line with home health care provider Amedisys' (AMED) M&A-led growth strategy, I view its pending acquisition of specialty home care provider Contessa positively. In particular, the addition of Contessa is an excellent fit with its strategy to expand its home healthcare capabilities, allowing it to...

Opal Investment Research on Seeking Alpha | July 18, 2021

Amedisys (AMED) Latest New York Assets Buyout Aids Home Health

The latest development remains in line with Amedisys' (AMED) ongoing efforts to expand footprint in key markets.

Yahoo | July 14, 2021

Hedge Funds Are Piling Into Amedisys Inc (AMED)

We at Insider Monkey have gone over 866 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of March 31st. In this article, we look at what those funds think of Amedisys Inc (NASDAQ:AMED) based on that data. […]

Yahoo | July 13, 2021

Read More 'AMED' Stories Here

AMED Price Returns

1-mo 6.41%
3-mo -3.42%
6-mo -9.29%
1-year 11.19%
3-year 178.35%
5-year 386.69%
YTD -11.15%
2020 75.73%
2019 42.53%
2018 122.18%
2017 23.65%
2016 8.42%

Continue Researching AMED

Here are a few links from around the web to help you further your research on Amedisys Inc's stock as an investment opportunity:

Amedisys Inc (AMED) Stock Price | Nasdaq
Amedisys Inc (AMED) Stock Quote, History and News - Yahoo Finance
Amedisys Inc (AMED) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9675 seconds.